BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and nine months ended September 30, 2021 and provided a business update.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced plans to participate in two upcoming investor conferences.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced its financial results for the third quarter and nine months ended September 30, 2021.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will report financial results for the quarter ended September 30, 2021 on Monday, November 15, 2021.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on the ARC-7 study of domvanalimab.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced that Zhenya Lindgardt has joined the Sera Board of Directors.

Amphastar Pharmaceuticals, Inc. reported results for the three months ended September 30, 2021.

MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States

Jiangsu Recbio Technology Co., Ltd. (“Recbio”), today announced preclinical data from its ReCOV a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine adjuvanted with squalene-based adjuvant BFA03.